Enovis (NYSE:ENOV) Sets New 12-Month Low – Here’s Why

Enovis Corporation (NYSE:ENOV) shares reached a new 52-week low on Thursday. The company traded as low as $17.16 and last traded at $17.19, with a volume of 170330 shares traded. The stock had previously closed at $17.61.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ENOV shares. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Evercore set a $32.00 price objective on shares of Enovis in a research note on Monday, July 6th. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Citizens Jmp decreased their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research report on Wednesday, September 2nd. Finally, UBS Group reaffirmed a “buy” rating and set a $44.00 target price on shares of Enovis in a report on Monday. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.50.

Enovis Trading Down 4.6%

The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The company has a market capitalization of $968.86 million, a price-to-earnings ratio of -0.87 and a beta of 1.37. The firm has a fifty day moving average price of $22.21 and a 200-day moving average price of $23.36.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same quarter in the previous year, the firm earned $0.79 earnings per share. Enovis’s revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts anticipate that Enovis Corporation will post 3.15 EPS for the current year.

Insider Activity at Enovis

In other news, CEO Damien Mcdonald acquired 13,035 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were acquired at an average cost of $19.15 per share, with a total value of $249,620.25. Following the completion of the purchase, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at $4,731,524.55. The trade was a 5.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Oliver Engert acquired 5,140 shares of the stock in a transaction on Thursday, September 3rd. The shares were purchased at an average price of $19.46 per share, with a total value of $100,024.40. Following the completion of the transaction, the insider owned 61,238 shares of the company’s stock, valued at approximately $1,191,691.48. This represents a 9.16% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 23,293 shares of company stock valued at $449,599 over the last 90 days. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

Large investors have recently modified their holdings of the business. Paradigm Capital Management Inc. NY acquired a new stake in shares of Enovis during the second quarter valued at about $28,533,000. Bank of America Corp DE acquired a new position in shares of Enovis in the second quarter valued at approximately $11,502,000. Man Group plc bought a new position in Enovis in the 2nd quarter valued at approximately $8,711,000. Front Street Capital Management Inc. raised its holdings in Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after buying an additional 384,124 shares during the last quarter. Finally, Private Management Group Inc. boosted its position in Enovis by 38.8% during the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock worth $28,257,000 after buying an additional 381,705 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.